Promising news at Elixir’s Nomgon-2 sends shares to record highs

|

Published 29-JUL-2020 10:23 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Elixir Energy Limited (ASX:EXR) has released highly promising news regarding its much anticipated Nomgon-2 appraisal well being drilled in Mongolia.

Investors were taken with the positive outcomes from Nomgon-1, and with management flagging drilling results for the end of July/early August there has been exceptional interest in the stock with its shares more than doubling in July from 3.7 cents to reach an all-time intraday record high of 9.5 cents, before closing at 8.4 cents.

Shareholders won’t be disappointed as total depth of the Nomgon-2 well was recently called at 550 metres, and logs have been run, measuring 91 metres of net coal in the well.

The main “100 series” coal seam was measured as having 51 net metres of coal.

Highlighting the quality of results to date in comparison with those achieved at Nomgon-1, Elixir’s managing director Neil Young said, “We are delighted with the results to date of the Nomgon-2 appraisal well, which has a thicker overall coal tally even than the exceptionally thick coals at Nomgon-1, and has added materially to the confirmed areal extent of the Nomgon-1 discovery.

It is therefore an important well in terms of adding to our contingent resource asset base and setting a great foundation for the ongoing appraisal work in the Nomgon sub-basin.

The Board’s congratulations goes out to our in-country team for a safe and seamless operation even under current COVID-19 limitations.”

More data, more share price action

The measurements are vertical intersections along hole, on the southern limb of the Nomgon syncline.

Gas content from numerous cores taken from the well is currently being measured in an on-site laboratory.

Preliminary results to date are consistent with the Nomgon-1, and the “raw” gas content numbers will be announced in the weeks to come.

The final “dry ash free” (DAF) figures, and the results of adsorption analysis, will follow thereafter, as the current logistics of cross border laboratory tests allow.

Down-hole permeability testing has been undertaken using an “injectivity fall off test” (IFOT) process, as was used at Nomgon-1.

Six separate tests have been successfully run so far, and results from these will be announced in the coming weeks.

The next phase of the company’s appraisal program in the Nomgon sub-basin will comprise the drilling of further step-out appraisal wells.

The first well will test the northern limb of the Nomgon syncline, and these wells will be low-cost stratigraphic wells with various objectives and with a range of risk profiles.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X